



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Myra A. Lipes et al. Art Unit : 1632
Serial No. : 09/770,601 Examiner : Anne-Marie Baker
Filed : January 26, 2001
Title : IMMUNOLOGICALLY PRIVILEGED CELLS AND USES THEREOF

MAIL STOP RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


INFORMATION DISCLOSURE STATEMENT

Copies of the references listed on the attached form PTO-1449 are enclosed.

This filing is being made with the filing of a Request for Continued Examination. No fee is required.

Respectfully submitted,

Date: 12-1-04



Janice L. Kugler
Reg. No. 50,429

Fish & Richardson P.C.
225 Franklin Street
Boston, MA 02110-2804
Telephone: (617) 542-5070
Facsimile: (617) 542-8906

20985322.doc

CERTIFICATE OF MAILING BY EXPRESS MAIL

Express Mail Label No. EV 330507664 VS
December 1, 2004
Date of Deposit

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 10276-015002	Application No. 09/770,601
Information Disclosure Statement by Applicant (Use several sheets if necessary) C:1 P E FEB 01 2004 A 37 CFR §1.98(b)		Applicant Myra A. Lipes et al.	
		Filing Date January 26, 2001	Group Art Unit 1632

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

Foreign Patent Documents or Published Foreign Patent Applications							
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation
							Yes No
	AL						
	AM						
	AN						
	AO						
	AP						

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	AQ	Couzin, Islet transplants face test of time. Science 306(5693):34-7 (2004)
	AR	Motoyoshi et al., Cellular characterization of pituitary adenoma cell line (AtT20 cell) transfected with insulin, glucose transporter type 2 (GLUT2) and glucokinase genes: insulin secretion in response to physiological concentrations of glucose. Diabetologia 41(12):1492-501 (1998)
	AS	The Diabetes Control and Complications Trial Research Group, The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New England J. Med. 329:977-986 (1993)
	AT	Tremblay et al., Pituitary-specific expression and glucocorticoid regulation of a proopiomelanocortin fusion gene in transgenic mice. Proc. Natl. Acad. Sci. U.S.A. 85(23):8890-4 (1988)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 10276-015002	Application No. 09/770,601
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Myra A. Lipes et al.	
		Filing Date January 26, 2001	Group Art Unit 1632

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	AU	Zhang, Diabetes Care, Risk of developing retinopathy in Diabetes Control and Complications Trial type 1 diabetic patients with good or poor metabolic control. 24:1275-79 (2001)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	